Biomedicines (Jul 2023)

Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis

  • Xiao-Jiang Chen,
  • Cheng-Zhi Wei,
  • Jun Lin,
  • Ruo-Peng Zhang,
  • Guo-Ming Chen,
  • Yuan-Fang Li,
  • Run-Cong Nie,
  • Yong-Ming Chen

DOI
https://doi.org/10.3390/biomedicines11072003
Journal volume & issue
Vol. 11, no. 7
p. 2003

Abstract

Read online

Background: Recently, many studies have explored the relationship between the expression of programmed death ligand 1 (PD-L1) and prognosis in gastric cancer, but there is still controversy. Additionally, few studies have specifically investigated the expression of PD-L1 in patients with peritoneal metastasis. Methods: Immunohistochemistry was used to analyze the expression of PD-L1 in gastric cancer patients with peritoneal metastasis. The combined positive score (CPS) was calculated to evaluate the expression of PD-L1, and the clinicopathological data were analyzed to explore prognostic significance. Results: In total, 147 gastric cancer patients with peritoneal metastasis were enrolled. The negative PD-L1 expression was defined as a CPS p = 0.015). Multivariate analysis demonstrated that a poor Eastern Cooperative Oncology Group performance score (ECOG PS) (p = 0.002) and severe peritoneal metastasis (p = 0.033) were significantly associated with poor survival, while palliative chemotherapy (p = 0.002) and high PD-L1 expression (p = 0.008) were independent and significantly favorable prognostic factors. Conclusions: Our study demonstrated that PD-L1 expression was widely presented in gastric cancer patients with peritoneal metastasis, while a CPS no less than 10 predicted better prognosis.

Keywords